2. Academic Validation
  3. Genomic scarring score predicts the response to PARP inhibitors in non-small cell lung cancer

Genomic scarring score predicts the response to PARP inhibitors in non-small cell lung cancer

  • NPJ Precis Oncol. 2024 Dec 26;8(1):291. doi: 10.1038/s41698-024-00777-6.
Katerina Tsilingiri # 1,  Anna Chalari # 1,  Georgia Christopoulou 2,  Alexandra Voutsina 3,  Pantelis Constantoulakis 2,  Κonstantinos Potaris 4,  Ioannis Vamvakaris 5,  Dora Hatzidaki 6,  Georgina Zachou 6,  Giannis Vatsellas 7,  Vassilis Georgoulias 6,  Athanasios Kotsakis 8,  Apostolos Klinakis 9
Affiliations

Affiliations

  • 1 Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
  • 2 Genotypos MSA, Private Molecular Biology and Cytogenetics Diagnostic Center, Athens, Greece.
  • 3 Institute of Chemical Biology, National Hellenic Research Foundation, Athens, Greece.
  • 4 Department of Thoracic Surgery, "SOTIRIA" General Hospital, Athens, Greece.
  • 5 Department of Pathology, "SOTIRIA" General Hospital, Athens, Greece.
  • 6 Hellenic Oncology Research Group, Athens, Greece.
  • 7 Greek Genome Centre, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
  • 8 Department of Medical Oncology, University General Hospital of Larisa, Larisa, Greece.
  • 9 Biomedical Research Foundation of the Academy of Athens, Athens, Greece. aklinakis@bioacademy.gr.
  • # Contributed equally.
PMID: 39725687 DOI: 10.1038/s41698-024-00777-6
Abstract

PARP inhibitors (PARPi) have shown efficacy in tumours harbouring mutations in homologous recombination repair (HRR) genes. Somatic HRR mutations have been described in patients with Non-Small Cell Lung Cancer (NSCLC), but PARP inhibitors (PARPi) are not yet a therapeutic option. Here we assessed the homologous recombination status of early-stage NSCLC and explored the therapeutic benefit of PARPi in preclinical models. The Genomic Scarring Score GSS (GSS) and HRR mutation profile of 136 patients were assessed. High GSS (h-GSS) was observed in 39 (28.7%) patients half of which carried pathogenic/likely pathogenic somatic HRR mutations. TP53 mutations were significantly enriched in h-GSS tumours (p < 0.001). Olaparib significantly delayed tumour growth in h-GSS but not l-GSS Patient-derived Xenografts (PDXs), while patients with h-GSS/TP53mut tumours respond favourably to Adjuvant platinum-based chemotherapy. Our functional data clearly support the idea that the use of GSS rather than the mutational status of HRR genes could select patients for administration of PARPi.

Figures
Products